Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Short Candidates -- Ignore unavailable to you. Want to Upgrade?

To: Robohogs who wrote (844)	4/25/2007 11:47:06 AM
From: tuck	Read Replies (1) \| Respond to of 897

I am actually still long ENCY (embarrassed <g> ). Ambrisentan approval is probably priced in (I'm still not sure it's a slam dunk, though). Now the other event . . . heh, heh . . . well, if you believe in trends, the FDA will say no again, go do another trial. Not sure what the odds of that really are; we're all just guessing as to the root problem with the NDA. What's the downside, you think, given approval in other countries? $2.50? Outright short, buy a bear spread . . . how to play? And thanks for your AVNR summation. Cheers, Tuck